Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1569 ARTÍCULOS , VIENDO DEL 1021 AL 1035

Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial

Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS; AAV2-NGF Study Team.

JAMA Neurol. 2018 Jul 1;75(7):834-841. doi: 10.1001/jamaneurol.2018.0233.

Targeting Alzheimer's disease with gene and cell therapies

Loera-Valencia R, Piras A, Ismail MAM, Manchanda S, Eyjolfsdottir H, Saido TC, Johansson J, Eriksdotter M, Winblad B, Nilsson P.

J Intern Med. 2018 Jul;284(1):2-36. doi: 10.1111/joim.12759.

Kognitives Training reduziert das Risiko eine Demenz zu entwickeln – nach aktuellen Daten – nicht

Steurer J.

Praxis (Bern 1994). 2018;107(7):399-400. doi: 10.1024/1661-8157/a002935.

Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease

Yildirim Simsir I, Soyaltin UE, Cetinkalp S.

Diabetes Metab Syndr. 2018 May;12(3):469-475. doi: 10.1016/j.dsx.2018.03.002. Epub 2018 Mar 16.

Have there been improvements in Alzheimer's disease drug discovery over the past 5 years?

Cacabelos R.

Expert Opin Drug Discov. 2018 Jun;13(6):523-538. doi: 10.1080/17460441.2018.1457645. Epub 2018 Apr 1.

The Alzheimer's Disease Home Hospice Knowledge Scale: development, validity and reliability

Sela-Katz P, Werner P.

Int J Palliat Nurs. 2018 Mar 2;24(3):108-114. doi: 10.12968/ijpn.2018.24.3.108.

Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study

Reed C, Belger M, Dell'Agnello G, Kahle-Wrobleski K, Sethuraman G, Hake A, Raskin J, Henley D.

Alzheimers Res Ther. 2018 Apr 3;10(1):36. doi: 10.1186/s13195-018-0360-4.

A Literature Review of Methodologies Used in Randomized Clinical Trials of Agitation in Alzheimer's Disease

Dubé S, Megerian JT, Malamut R.

J Prev Alzheimers Dis. 2018;5(2):120-133. doi: 10.14283/jpad.2018.17.

The Integrated Alzheimer's Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial

Wessels AM, Andersen SW, Dowsett SA, Siemers ER.

J Prev Alzheimers Dis. 2018;5(2):134-136. doi: 10.14283/jpad.2018.10.

Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer's Disease

Burstein AH, Sabbagh M, Andrews R, Valcarce C, Dunn I, Altstiel L.

J Prev Alzheimers Dis. 2018;5(2):149-154. doi: 10.14283/jpad.2018.18.

Addressing Alzheimer's Disease in Asian American and Pacific Islander Older Adults: An Action Guide for Service Providers

Eller N, Belza B.

J Gerontol Nurs. 2018 Apr 1;44(4):3-4. doi: 10.3928/00989134-20180313-01.

A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil

Fullerton T, Binneman B, David W, Delnomdedieu M, Kupiec J, Lockwood P, Mancuso J, Miceli J, Bell J.

Alzheimers Res Ther. 2018 Apr 5;10(1):38. doi: 10.1186/s13195-018-0368-9.

New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease

Zhong KL, Chen F, Hong H, Ke X, Lv YG, Tang SS, Zhu YB.

Metab Brain Dis. 2018 Aug;33(4):1009-1018. doi: 10.1007/s11011-018-0227-1. Epub 2018 Apr 6.

Informed consent to research trials on Alzheimer's disease: How to foster research without infringing upon the patient's right to self-determination

Montanari Vergallo G, Cisale GY, di Luca NM, Marinelli E, Zaami S.

Pharmacol Res. 2018 Jun;132:69-71. doi: 10.1016/j.phrs.2018.04.001. Epub 2018 Apr 4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias